Taken together, these findings suggest that METTL3‐mediated SREBP1c upregulation contributes to AKI and its progression to CKD through disrupting mitochondrial energy metabolism via transcriptionally suppressing YME1L1. Here, SREBF1 is linked to chronic kidney disease.